US20130029339A1 - Use of microvesicles in analyzing kras mutations - Google Patents

Use of microvesicles in analyzing kras mutations Download PDF

Info

Publication number
US20130029339A1
US20130029339A1 US13/395,354 US201013395354A US2013029339A1 US 20130029339 A1 US20130029339 A1 US 20130029339A1 US 201013395354 A US201013395354 A US 201013395354A US 2013029339 A1 US2013029339 A1 US 2013029339A1
Authority
US
United States
Prior art keywords
microvesicles
nucleic acid
disease
subject
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/395,354
Other languages
English (en)
Inventor
Johan Karl Olov Skog
Xandra O. Breakefield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US24102009P priority Critical
Application filed by General Hospital Corp filed Critical General Hospital Corp
Priority to PCT/US2010/048310 priority patent/WO2011031892A1/en
Priority to US13/395,354 priority patent/US20130029339A1/en
Publication of US20130029339A1 publication Critical patent/US20130029339A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
US13/395,354 2009-09-09 2010-09-09 Use of microvesicles in analyzing kras mutations Abandoned US20130029339A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US24102009P true 2009-09-09 2009-09-09
PCT/US2010/048310 WO2011031892A1 (en) 2009-09-09 2010-09-09 Use of microvesicles in analyzing kras mutations
US13/395,354 US20130029339A1 (en) 2009-09-09 2010-09-09 Use of microvesicles in analyzing kras mutations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/395,354 US20130029339A1 (en) 2009-09-09 2010-09-09 Use of microvesicles in analyzing kras mutations

Publications (1)

Publication Number Publication Date
US20130029339A1 true US20130029339A1 (en) 2013-01-31

Family

ID=43732798

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/395,354 Abandoned US20130029339A1 (en) 2009-09-09 2010-09-09 Use of microvesicles in analyzing kras mutations
US14/805,001 Pending US20150322532A1 (en) 2009-09-09 2015-07-21 Use of microvesicles in analyzing mutations

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/805,001 Pending US20150322532A1 (en) 2009-09-09 2015-07-21 Use of microvesicles in analyzing mutations

Country Status (3)

Country Link
US (2) US20130029339A1 (de)
EP (1) EP2475989A4 (de)
WO (1) WO2011031892A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201092A1 (en) * 2013-06-11 2014-12-18 Dana-Farber Cancer Institute, Inc. Non-invasive blood based monitoring of genomic alterations in cancer
WO2016077709A1 (en) * 2014-11-14 2016-05-19 Liquid Genomics, Inc. Use of circulating cell-free rna for diagnosis and/or monitoring cancer
US9939443B2 (en) 2012-12-19 2018-04-10 Caris Life Sciences Switzerland Holdings Gmbh Compositions and methods for aptamer screening
US9958448B2 (en) 2012-10-23 2018-05-01 Caris Life Sciences Switzerland Holdings Gmbh Aptamers and uses thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
KR20140067001A (ko) * 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
WO2013028788A1 (en) 2011-08-22 2013-02-28 Exosome Diagnostics, Inc. Urine biomarkers
EP2776587A4 (de) 2011-11-10 2015-07-15 Exosome Diagnostics Inc Liquor-assay
WO2013074438A1 (en) * 2011-11-17 2013-05-23 The Johns Hopkins University Differential identification of pancreatic cysts
WO2013134786A2 (en) * 2012-03-09 2013-09-12 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
CA2887058A1 (en) * 2012-10-03 2014-04-10 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
CN106029900B (zh) 2013-08-06 2020-02-28 外来体诊断公司 尿生物标志物群、基因表达特征及其使用方法
WO2015144184A1 (en) * 2014-03-26 2015-10-01 University Of Copenhagen Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer
US10266895B2 (en) 2014-11-05 2019-04-23 Hitachi Chemical Company Ltd. Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
WO2016077537A1 (en) * 2014-11-12 2016-05-19 Hitachi Chemical Co., Ltd. Method and device for diagnosing organ injury

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184046A1 (en) * 2008-11-12 2010-07-22 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
US20110081651A1 (en) * 2005-06-28 2011-04-07 Genentech, Inc. Egfr and kras mutations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788780B1 (fr) * 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
US20080268429A1 (en) * 2004-06-02 2008-10-30 Sourcepharm, Inc. Rna - Containing Microvesicles and Methods Therefor
JP5676277B2 (ja) * 2008-02-01 2015-02-25 ザ ジェネラル ホスピタル コーポレイション 医学的疾患および医学的状態の診断、予後および治療におけるマイクロベシクルの使用
CA2764468A1 (en) * 2009-06-05 2010-12-09 Myriad Genetics, Inc. Methods of detecting cancer comprising screening for mutations in the apc, egfr, kras, pten and tp53 genes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110081651A1 (en) * 2005-06-28 2011-04-07 Genentech, Inc. Egfr and kras mutations
US20100184046A1 (en) * 2008-11-12 2010-07-22 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9958448B2 (en) 2012-10-23 2018-05-01 Caris Life Sciences Switzerland Holdings Gmbh Aptamers and uses thereof
US9939443B2 (en) 2012-12-19 2018-04-10 Caris Life Sciences Switzerland Holdings Gmbh Compositions and methods for aptamer screening
WO2014201092A1 (en) * 2013-06-11 2014-12-18 Dana-Farber Cancer Institute, Inc. Non-invasive blood based monitoring of genomic alterations in cancer
WO2016077709A1 (en) * 2014-11-14 2016-05-19 Liquid Genomics, Inc. Use of circulating cell-free rna for diagnosis and/or monitoring cancer

Also Published As

Publication number Publication date
US20150322532A1 (en) 2015-11-12
EP2475989A4 (de) 2013-02-27
EP2475989A1 (de) 2012-07-18
WO2011031892A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
Freedman et al. Diverse human extracellular RNAs are widely detected in human plasma
Garcia-Murillas et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
JP2017131244A (ja) 核酸分析
Peeters et al. Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting
Balaj et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences
Kumar et al. MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease
Hall et al. Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation
Ziats et al. Aberrant expression of long noncoding RNAs in autistic brain
Rollins et al. Analysis of whole genome biomarker expression in blood and brain
Chen et al. Correlation between DNA methylation and gene expression in the brains of patients with bipolar disorder and schizophrenia
AU2014210676B2 (en) Methods of Using miRNA for Detection of In Vivo Cell Death
KR101583546B1 (ko) 유전자 다형성을 이용한 소라페닙 치료에 대한 반응성 예측방법
Wilflingseder et al. miRNA profiling discriminates types of rejection and injury in human renal allografts
Tian et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas
US20160348178A1 (en) Disease-associated genetic variations and methods for obtaining and using same
Noerholm et al. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls
Sievert et al. Duplication of 7q34 in pediatric low‐grade astrocytomas detected by high‐density single‐nucleotide polymorphism‐based genotype arrays results in a novel BRAF fusion gene
JP2018088922A (ja) 医学的疾患および医学的状態の診断、予後および治療におけるマイクロベシクルの使用
JP5755569B2 (ja) 肺癌を検出する方法
Bonnet et al. An innovative strategy for the molecular diagnosis of Usher syndrome identifies causal biallelic mutations in 93% of European patients
Weber et al. Frequent loss of chromosome 9, homozygous CDKN2A/p14 ARF/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas
Dimassi et al. A subset of genomic alterations detected in rolandic epilepsies contains candidate or known epilepsy genes including GRIN 2A and PRRT 2
EP3191628A1 (de) Identifikation und verwendung von zirkulierenden nukleinsäuren
AU2004213871B2 (en) Use of intronic RNA to measure gene expression
JP2020127416A (ja) ヘテロ接合性の消失(loss of heterozygosity)を評価するための方法および材料

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION